CRISPR‐Cas targeted plasmid integration into mammalian cells via non‐homologous end joining
Citations Over TimeTop 10% of 2015 papers
Abstract
Mammalian cells are widely used for the production of therapeutic recombinant proteins, as these cells facilitate accurate folding and post-translational modifications often essential for optimum activity. Targeted insertion of a plasmid harboring a gene of interest into the genome of mammalian cells for the expression of a desired protein is a key step in production of such biologics. Here we show that a site specific double strand break (DSB) generated both in the genome and the donor plasmid using the CRISPR-Cas9 system can be efficiently used to target ∼5 kb plasmids into mammalian genomes via nonhomologous end joining (NHEJ). We were able to achieve efficiencies of up to 0.17% in HEK293 cells and 0.45% in CHO cells. This technique holds promise for quick and efficient insertion of a large foreign DNA sequence into a predetermined genomic site in mammalian cells.
Related Papers
- → Increasing the efficiency of CRISPR‐Cas9‐VQR precise genome editing in rice(2017)97 cited
- → Orthogonal Cas9–Cas9 chimeras provide a versatile platform for genome editing(2018)36 cited
- → Elevated expression of exogenous RAD51 enhances the CRISPR/Cas9-mediated genome editing efficiency(2023)10 cited
- → Editing Aspergillus terreus using the CRISPR-Cas9 system(2022)8 cited
- → An assessment of genome-editing efficiency of a newly developed Cas9 in C. elegans(2022)2 cited